Amarin's sad and lonely Vascepa launch party
The biopharma company raises $100 million in debt financing because potential partners aren't interested in the cholesterol-reducing fish-oil pill.
By Adam Feurerstein
Amarin (AMRN) held a Vascepa launch conference call Thursday night. Unfortunately, Amarin should have done this call on July 27, the day after the lipid-lowering prescription fish-oil pill was approved.
Launching any drug is hard. Launching a drug 133 days after it was approved is really hard. Yet that's the deep hole Amarin management has dug for itself after wasting precious time on a quixotic quest to land a Big Pharma marketing partner (or even sillier) a takeout suitor.
On Thursday night, Amarin announced plans to raise $100 million in debt financing and the intention to hire 250 to 300 sales representatives. This is the dreaded Vascepa "go it alone" launch strategy.
Amarin shares are down almost 20% to $9.62 in Friday trading.
On a brief conference call, Amarin CEO Joe Zakrzewski tried his best to put an upbeat spin on the bad news. He reiterated his previous claims that "all options are still on the table" and "partner discussions were still active."
So active that Amarin needed to raise $100 million in debt?
On the never-ending topic of Vascepa's New Chemical Entity (NCE) status, as reported on TheStreet, Zakrzewski insisted Amarin still had no idea how or when the FDA would issue a ruling. An update of the Orange Book is expected next week and Amarin bulls were hoping to get some positive news.
Zakrzewski called the lack of an NCE decision an "overhang" for the company but also "much ado about nothing." He didn't bother to explain how something could be both negative and irrelevant, but then, common sense is in short supply at Amarin HQ.
Even if FDA does grant NCE status to Vascepa, it's hard to see how it matters now. Amarin clearly has no serious interest from potential suitors or partners. The Amarin bulls who believed last month's delayed decision to hire a sales force signaled a pending deal were very wrong.
Amarin wouldn't address the issue directly Thursday night but it seems clear now that a delay in finalizing the $100 million debt rescue package was the only reason for not announcing the sales force hires at the end of November, as previously expected.
Not everyone is mired in the gloom. Amarin shorts are happy, but so are Zakrzewski and the other executives who, according to TheStreet, sold millions of dollars in company stock right after Vascepa was approved. Those insider sales in the $13 to $14 range look even smarter now.
Amarin bulls are kicking themselves for not following Zakrzewski's lead.
More from TheStreet.com
- The worst company to work for in America
- The 5 dumbest things on Wall Street: Dec 7
- Biotech mailbag – YM Bio, Infinity, Delcath
Copyright © 2014 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
As geopolitical tensions threaten to spin out of control, investors are wondering how best to position their portfolios for the global turmoil.
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.